Non-exclusive license for Solid Biosciences’ proprietary, next-generation myotropic capsid, AAV-SLB101, to accelerate development of KNA-155 for dysferlinopathy SEATTLE, September 23, 2025--(BUSINESS ...
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain. The Dutch biotech has secured an exclusive option to evaluate ...
CAMBRIDGE, United Kingdom, September 09, 2025--(BUSINESS WIRE)--Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product ...
The FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform ...
Assembly and budding of a virus from a membrane microdomain. Viruses have an outer protein shell called a capsid which surrounds the viral nucleic acid. Enveloped viruses, such as HIV, have an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback